Maxime Verhoeven

229 Summary and general discussion REFERENCES 1. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 79 , 685–699 (2020). 2. Ramiro, S. et al. Is treat-to-target really working in rheumatoid arthritis? A longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). Ann. Rheum. Dis. 79 , 453–459 (2020). 3. Raza, K. & Filer, A. The therapeutic window of opportunity in rheumatoid arthritis: does it ever close ? Ann. Rheum. Dis. 74 , 793–794 (2015). 4. De Rotte, M. C. et al. Development and validation of a prognostic multivariable model to predict insufficient clinical response tomethotrexate in rheumatoid arthritis. PLoS One 13 , e0208534 (2018). 5. Teitsma, X. M., Marijnissen, A. C. A., Bijlsma, J. W. J., Lafeber, F. P. J. & Jacobs, J. W. G. Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials. Arthritis Res. Ther. 18 , 211 (2016). 6. Müskens, W. D., Rongen-van Dartel, S. A. A., van Riel, P. L. C. M. & Adang, E. M. M. Does Etanercept biosimilar prescription in a rheumatology center bend the medication cost curve? In press, J. Rheumatol. November 2020. 7. Triantafyllias, K., Heller, C., de Blasi, M., Galle, P. & Schwarting, A. Diagnostic value of optical spectral transmission in rheumatoid arthritis: associations with clinical characteristics and comparison with joint ultrasonography. J. Rheumatol. 47 , 1314–1322 (2020). 8. Pincus, T. & Segurado, O. G. Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. Ann. Rheum. Dis. 65 , 820–822 (2006). 9. Safy, M. et al. Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second computer-assisted management in early rheumatoid arthritis trial. Ann. Rheum. Dis. 76 , 1432–1435 (2017). 10. Goekoop-Ruiterman, Y. P. M. et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52 , 3381–3390 (2005). 11. O’Dell, J. R. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum. 46 , 283–285 (2002). 12. Hsieh, P. H. et al. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. Ann. Rheum. Dis. 79 , S771–S777 (2020). 13. van der Hout, W. B. et al. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 61 , 291–299 (2009). 14. Salliot, C. & van der Heijde, D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann. Rheum. Dis. 68 , 1100–1104 (2009). 15. Autoriteit Consument & Markt. Sectoronderzoek TNF-alfaremmers . https://www.acm.nl/sites/ default/files/documents/2019-09/sectoronderzoek-tnf-alfaremmers.pdf (2019). 16. van Nies, J. A. B., Tsonaka, R., Fautrel, B. & van Mil-van der Helm, A. H. M. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann. Rheum. Dis. 74 , 806–812 (2015). 17. Zorginstituut Nederland. Ziektelast in de praktijk . (2018). 18. Zorginstituut Nederland. Kosteneffectiviteit in de praktijk . (2015). 19. Scott, D. L. &Houssien, D. A. Joint assessment in rheumatoid arthritis. Br. J. Rheumatol. 35 , 14–18 (1996). 20. Jacobs, J. W. G., ten Cate, D. F. & van Laar, J. M. Monitoring of rheumatoid arthritis disease activity in individual patients: still a hurdle when implementing the treat-to-target principle in daily clinical practice. Rheumatology 54 , 959–961 (2015). 13